NeurologyLive® Brain Games: RNA Therapeutics for Neuromuscular Disorders

Welcome to NeurologyLive^® Brain Games! This weekly quiz series, which goes live every Sunday morning, will feature questions on a variety of clinical and historical neurology topics, written by physicians, clinicians, and experts in the fields of neurological care and advocacy.

Test your mettle each week with 3 questions that cover a variety of aspects in the field of neurology, with a focus on dementia and Alzheimer disease, epilepsy and seizure disorders, headache and migraine, movement disorders, multiple sclerosis, neuromuscular disorders, sleep disorders, and stroke and cerebrovascular disease.

This week’s questions include the theme of RNA therapeutics for neuromuscular disorders.

Quiz Questions

1. Question 1: What is the primary mechanism of action of antisense oligonucleotides (ASOs) in treating neuromuscular disorders?
   • a) Increasing protein production
   • b) Degrading target mRNA
   • c) Enhancing gene transcription
   • d) Blocking protein-protein interactions
2. Question 2: Spinraza (nusinersen) is an ASO approved for the treatment of spinal muscular atrophy (SMA). What specific mRNA target does Spinraza address?
   • a) SMN1
   • b) SMN2
   • c) ACTB
   • d) MYO7A
3. Question 3: What is a key challenge in delivering RNA therapeutics to skeletal muscle, a primary target in many neuromuscular diseases?
   • a) High immunogenicity of RNA
   • b) Limited ability of RNA to cross cell membranes
   • c) Rapid degradation of RNA in the bloodstream
   • d) All of the above

Answer Key

1. Answer: b) Degrading target mRNA. ASOs bind to specific mRNA sequences, leading to their degradation and reducing protein production.
2. Answer: b) SMN2. Spinraza modifies splicing of the SMN2 gene to increase production of functional SMN protein, compensating for the deficiency of SMN1 in SMA.
3. Answer: d) All of the above. Effective delivery of RNA therapeutics requires overcoming challenges related to immunogenicity, cell permeability, and RNA stability.

Key takeaways

• RNA therapeutics, notably ASOs, represent a promising approach for treating neuromuscular disorders by targeting the root cause of disease at the mRNA level.
• Spinraza demonstrates the clinical efficacy of ASOs in SMA, paving the way for the development of similar therapies for other genetic neuromuscular conditions.
• Delivery challenges remain a significant hurdle in the field, with ongoing research focused on improving RNA stability, cell uptake, and reducing off-target effects.

Publication Date: 2025/09/07 10:21:55